<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346837</url>
  </required_header>
  <id_info>
    <org_study_id>CA017-051</org_study_id>
    <nct_id>NCT03346837</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-Label, Four-Cohort, Parallel Design Study to Evaluate the Effect of Itraconazole or Rifampin on the Single-Dose Pharmacokinetics of BMS-986205 in Normal Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and
      tolerability of BMS-986205.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, parallel design study in healthy participants to assess the effects
      of itraconazole and rifampin on the single-dose pharmacokinetics of BMS-986205. Safety and
      tolerability data to be collected and assessed as well.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 22, 2017</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">December 20, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 25 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to time of last quantifiable concentration (AUC(0-T))</measure>
    <time_frame>Up to 25 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero extrapolated to infinite time (AUC(INF))</measure>
    <time_frame>Up to 25 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 25 days</time_frame>
    <description>Safety and tolerability as measured by incidence of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 76 days</time_frame>
    <description>Safety and tolerability as measured by incidence of SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with electrocardiogram abnormalities</measure>
    <time_frame>Up to 25 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with physical examination findings abnormalities</measure>
    <time_frame>Up to 25 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinical laboratory abnormalities</measure>
    <time_frame>Up to 25 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Malignancies Multiple</condition>
  <arm_group>
    <arm_group_label>Inhibition (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose BMS-986205</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhibition (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral itraconazole doses for 24 days; single oral dose BMS-986205 on day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose BMS-986205</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral rifampin doses for21 days; single oral dose BMS-986205 on day 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986205</intervention_name>
    <description>BMS-986205</description>
    <arm_group_label>Inhibition (Cohort 1)</arm_group_label>
    <arm_group_label>Inhibition (Cohort 2)</arm_group_label>
    <arm_group_label>Induction (Cohort 3)</arm_group_label>
    <arm_group_label>Induction (Cohort 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>Inhibition (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Induction (Cohort 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index 18.0 to 32.0 kg/m2, inclusive

          -  Must have normal renal function demonstrated by GFR, calculated by Chronic Kidney
             Disease Epidemiology Collaboration formula

          -  Women must not be of childbearing potential (cannot become pregnant)

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  History of glucose-6-phosphodiesterase (G6PD) deficiency

          -  Personal or family history of cytochrome b5 reductase deficiency

        Other protocol defined inclusion / exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Briston-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

